Doctors Develop World’s First Functional 3D Printed Human Lung

A biotech company supported by a university claims to be revolutionizing research with its groundbreaking 3D lung development, according to the company's spokesperson. ImmuONE, based in Milton Keynes, has engineered a human lung model for testing and evaluating inhaled medications, as well as consumer products such as fragrances and sprays, facilitating their entry into the market. The company, now equipped with a laboratory in Stevenage, has ambitions for expansion into the United States.

Dr. Victoria Hutter, representing the company, attributes their "eureka moment" to the assistance provided by the University of Hertfordshire. This university leads a new Healthcare consortium, in partnership with Imperial College London and Cranfield University, aimed at supporting more ventures like ImmuONE in Milton Keynes. The initiative aims to assist 15 healthcare start-ups in Hertfordshire, Bedfordshire, and London, offering up to £35,000 in funding alongside guidance to foster a positive societal impact within the healthcare sector.

Reflecting on the journey, Dr. Hutter, also a professor of vitro toxicology at the university, expresses enthusiasm for the development of their 3D lung, acknowledging both the excitement and challenges encountered. She emphasizes the satisfaction derived from witnessing their product contribute positively to research, while highlighting ongoing endeavors in collaboration with clients.

Dr. Abigail Martin, another member of the team, shares insights from her experience in drug development projects, underscoring the transformative potential of new medications for patients. Seeking a more efficient approach, she embarked on a quest for alternatives, which culminated in the creation of the 3D lung model. This innovation facilitates the testing of various products, ranging from fragrances to paints, thereby reducing reliance on animal testing. ImmuONE asserts its unique position as the sole provider of such a 3D lung globally and aims to attract further investment to fuel business expansion in the USA.

Professor Wendy Wills, serving as the pro-vice-chancellor for research and enterprise at the University of Hertfordshire, applauds the initiative as an avenue to attract individuals with a pioneering spirit capable of revolutionizing healthcare and improving lives. She underscores the university's strong track record of collaborating with industry to drive impactful change.